Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 8.04 billion. The enterprise value is 8.36 billion.
| Market Cap | 8.04B |
| Enterprise Value | 8.36B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 223.04 million shares outstanding. The number of shares has decreased by -0.42% in one year.
| Current Share Class | 223.04M |
| Shares Outstanding | 223.04M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | n/a |
| Float | 35.22M |
Valuation Ratios
The trailing PE ratio is 67.04.
| PE Ratio | 67.04 |
| Forward PE | n/a |
| PS Ratio | 6.36 |
| PB Ratio | 4.37 |
| P/TBV Ratio | 5.82 |
| P/FCF Ratio | 28.37 |
| P/OCF Ratio | 26.00 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.34, with an EV/FCF ratio of 29.48.
| EV / Earnings | 69.66 |
| EV / Sales | 6.61 |
| EV / EBITDA | 27.34 |
| EV / EBIT | 48.68 |
| EV / FCF | 29.48 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.69 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 1.72 |
| Debt / FCF | 1.85 |
| Interest Coverage | 13.14 |
Financial Efficiency
Return on equity (ROE) is 6.83% and return on invested capital (ROIC) is 4.51%.
| Return on Equity (ROE) | 6.83% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 4.51% |
| Return on Capital Employed (ROCE) | 8.28% |
| Revenue Per Employee | 7.31M |
| Profits Per Employee | 693,277 |
| Employee Count | 173 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Orient Pharma has paid 58.63 million in taxes.
| Income Tax | 58.63M |
| Effective Tax Rate | 32.83% |
Stock Price Statistics
The stock price has increased by +29.21% in the last 52 weeks. The beta is -0.08, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | +29.21% |
| 50-Day Moving Average | 35.22 |
| 200-Day Moving Average | 34.56 |
| Relative Strength Index (RSI) | 49.45 |
| Average Volume (20 Days) | 35,188 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.26 billion and earned 119.94 million in profits. Earnings per share was 0.54.
| Revenue | 1.26B |
| Gross Profit | 656.44M |
| Operating Income | 171.64M |
| Pretax Income | 178.57M |
| Net Income | 119.94M |
| EBITDA | 278.36M |
| EBIT | 171.64M |
| Earnings Per Share (EPS) | 0.54 |
Balance Sheet
The company has 210.55 million in cash and 525.41 million in debt, giving a net cash position of -314.86 million or -1.41 per share.
| Cash & Cash Equivalents | 210.55M |
| Total Debt | 525.41M |
| Net Cash | -314.86M |
| Net Cash Per Share | -1.41 |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 8.25 |
| Working Capital | 322.04M |
Cash Flow
In the last 12 months, operating cash flow was 309.28 million and capital expenditures -25.83 million, giving a free cash flow of 283.45 million.
| Operating Cash Flow | 309.28M |
| Capital Expenditures | -25.83M |
| Free Cash Flow | 283.45M |
| FCF Per Share | 1.27 |
Margins
Gross margin is 51.94%, with operating and profit margins of 13.58% and 9.49%.
| Gross Margin | 51.94% |
| Operating Margin | 13.58% |
| Pretax Margin | 14.13% |
| Profit Margin | 9.49% |
| EBITDA Margin | 22.03% |
| EBIT Margin | 13.58% |
| FCF Margin | 22.43% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.42% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.49% |
| FCF Yield | 3.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 5.94 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.94 |
| Piotroski F-Score | 5 |